Johnson & Johnson (JNJ) Change in Cash (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Cash of -$1.3 billion for Q2 2026, down 163.97% sequentially from $2.0 billion in Q1 2026, and up 93.64% YoY from -$653.8 million in Q2 2025.
Johnson & Johnson (JNJ) Change in Cash (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Change in Cash for 18 years, with the latest figure at -$1.3 billion in Q2 2026.
- Quarterly Change in Cash rose 93.64% year-over-year to -$1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 129.28% YoY) and the FY2025 annual result came in at -$4.4 billion, down 295.73% from the prior year.
- Change in Cash eased to -$1.3 billion in Q2 2026 per JNJ's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Change in Cash peaked at $14.4 billion in Q1 2025 and troughed at -$19.9 billion in Q2 2025.
- A 5-year average of -$106.8 million and a median of -$470.5 million in 2024 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2023 and 2025: Change in Cash jumped 416.55% in 2023, then sank 3244.03% in 2025.
- Over 5 years, Change in Cash stood at -$4.0 billion in 2022, then soared by 152.96% to $2.1 billion in 2023, then jumped by 93.57% to $4.1 billion in 2024, then slumped by 64.17% to $1.5 billion in 2025, then slumped by 185.66% to -$1.3 billion in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$1.3 billion, $2.0 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -14.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -1.27 Bn |
| Mar 29, 2026 | 1.98 Bn |
| Dec 28, 2025 | 1.48 Bn |
| Sep 28, 2025 | -346.00 Mn |
| Jun 29, 2025 | -19.90 Bn |
| Mar 30, 2025 | 14.37 Bn |
| Dec 29, 2024 | 4.13 Bn |
| Sep 29, 2024 | -4.90 Bn |
| Jun 30, 2024 | -595.00 Mn |
| Mar 31, 2024 | 3.61 Bn |
| Dec 31, 2023 | 2.13 Bn |
| Oct 1, 2023 | -1.46 Bn |
| Jul 2, 2023 | -5.68 Bn |
| Apr 2, 2023 | 12.74 Bn |
| Jan 1, 2023 | -3.98 Bn |
| Apr 3, 2022 | -4.02 Bn |
| Oct 3, 2021 | 3.27 Bn |
| Jul 4, 2021 | 1.66 Bn |
| Apr 4, 2021 | -1.31 Bn |
| Jan 3, 2021 | -4.98 Bn |